Please login to the form below

Not currently logged in
Email:
Password:

real world evidence

This page shows the latest real world evidence news and features for those working in and with pharma, biotech and healthcare.

Who's calling the shots in European healthcare?

Who's calling the shots in European healthcare?

greater real-world evidence (RWE)? ... Maintain and develop Europe’s world-class IP system. Advance Europe’s Smart trade agenda.

Latest news

More from news
Approximately 11 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • Real-world studies Real-world studies

    by Bill Row. How is real-world evidence (RWE) reshaping the way companies think about research strategies and provide data to their stakeholders? ... Bill Row is Divisional Principal of Real-World Evidence Strategy &Analytics at ICON plc.

  • The evolution of real-world studies The evolution of real-world studies

    How industry and regulators are using real-world data. The use of real-world evidence (RWE) is evolving quickly. . ... Pfizer brought Ibrance to market using data from randomised controlled trials (RCTs) in women, before supplementing that evidence with

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    22. DR HARIETTA ELEFTHEROCHORINOU. AI pioneer. After a wave of hype, AI is now starting to show its value across the life sciences sector, harnessing big data and real-world evidence ... applications in pharma and real-world ML/AI platforms for scalable

  • Is it time for a more integrated and human-centric approach to Medical Affairs leadership? Is it time for a more integrated and human-centric approach to Medical Affairs leadership?

    lead the communication of increasingly complex science and the implementation of trials that yield real-world evidence (RWE) to demonstrate clinical value. ... to create a single voice with which to speak to the external world; a voice that must remain

  • The UK’s new medicines pricing deal – opportunities and risks for pharma The UK’s new medicines pricing deal – opportunities and risks for pharma

    The ambition is for more ‘real-world evidence’, which could be included on an indication-specific basis. ... This is further evidence of the influence of NHSE. New incentives to greater cost-effectiveness.

More from intelligence
Approximately 9 fully matching, plus 52 partially matching documents found.

Latest appointments

  • Remi Gauchoux joins Carenity Remi Gauchoux joins Carenity

    Gauchoux has a 20-year international experience in healthcare and the CRO industries with expertise in late phase and real-world evidence analysis.

  • Dr Ameet Nathwani moves from Novartis to Sanofi Dr Ameet Nathwani moves from Novartis to Sanofi

    Oliver Brandicourt, Sanofi's chief executive officer, said: “Our industry is experiencing increased pressure to support reimbursement with customized data from real-world evidence, demonstrate ongoing benefit-risk of registered products

  • EMA's Dr Stella Blackburn joins Quintiles EMA's Dr Stella Blackburn joins Quintiles

    Cynthia Verst, president, real world and late phase research at Quintiles, said: “Stella's experience developing innovative risk management solutions is a tremendous addition to our team. ... She said: “Together with my colleagues at Quintiles, I aim

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics